Abiopharma

🔍 TANG KEVIN (Executive)

Company: Boundless Bio, Inc. (BOLD)

Report Date: 2026-07-17

Detailed Transactions and Holdings:

• Acquired 265 shares of Common Stock at $2.44 per share (Direct)
  Date: 2026-07-17 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,854,337.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 1,623 shares of Common Stock at $2.44 per share (Direct)
  Date: 2026-07-20 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,855,960.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 2,975 shares of Common Stock at $2.44 per share (Direct)
  Date: 2026-07-21 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,858,935.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The prices reported are weighted-average prices. These shares were all purchased at $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1.
• F2: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 893,434 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 655,170 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.